HCL-FOUNDATION
16.2.2021 11:37:15 CET | Business Wire | Press release
HCL Foundation, the corporate social responsibility arm of HCL Technologies Ltd., today announced the winners of the sixth round of the HCL Grant, a flagship program dedicated to strengthening India’s “fifth estate” of NGOs working towards nation building.
The three NGOs, one each in the development areas of environment, health, and education, will each receive a grant of INR 5 crore ($685,000) for a three to five-year project. In addition, two finalists in each category will receive a one-year grant of INR 25 lakhs ($34,000), making a total grant of INR 16.5 crore.
HCL Foundation, which this year celebrates a decade of building strong and robust communities, is committed to contributing to the nation’s growth curve. Under its HCL Grant program, the Foundation has so far committed a more than INR 60 crore ($8.26 Million), excluding this year’s grants. Recognized as one of the most sought-after validations amongst NGO ecosystems in India, the HCL Grant has in the past five years reached over 733,000 beneficiaries. The Grant aims to touch the lives of at least 1.72 million people in 8,598 villages in 70 districts across 18 states and two union territories of India.
The winning NGOs of HCL Grant 2021 were:
- Saahas (Environment)
- India Health Action Trust (Health)
- Child Rights and You (Education)
The NGOs were chosen after an 8-month review of thousands of applications by an eminent jury, monitored and audited by Grant Thornton, the governance partner of HCL Grant. The jury consisted of: Ms. Robin Abrams, Director, HCL Technologies, and Chairperson of the jury; Mr. Suresh Narayanan, Chairman and Managing Director, Nestle India Limited; Mr. B. S. Baswan, former Director, Indian Institute of Public Administration, and former Secretary, Human Resource Development ministry; Ms. Pallavi Shroff, Managing Partner, Shardul Amarchand Mangaldas & Co. law firm; Dr. Richard Lariviere, President Emeritus, Field Museum (Chicago), and former President, University of Oregon; and Mr. Shiv Nadar, Founder of HCL, Chief Strategy Officer of HCL Technologies, and Founder and Chairman of the Shiv Nadar Foundation.
“The past year was a unique year of resilience and transformation that taught us how to transcend barriers and keep going even in the face of adversity,” said Ms. Abrams. “Despite the pandemic, the robustness demonstrated by our NGO partners, experts, jury members and the entire team is commendable. The passion and zeal of our NGO partners to bring in scalable and replicable solutions have created systemic shifts across geographies, lending velocity to the sustainable development agenda. The winners and finalists of this year’s Grant also have significant stories to tell, with visible on-the-ground impact. My best wishes to these NGOs, who are addressing some of the most pressing issues in the key development categories of environment, health, and education in the most remote corners of the country.”
Ms. Nidhi Pundhir, Director, HCL Foundation, said: “The year 2020 has been both special and unusual. Special, in that the Foundation is completing ten years of facilitating high-impact, sustainable socio-economic development in rural India. Unusual, in that the NGOs we support had to deal with unprecedented challenges posed by the pandemic and various natural disasters, while initiating and implementing their developmental projects. What is inspiring about these NGOs is that they are treating COVID-19 as the ‘new normal’ and are continuing with their path-breaking projects without a pause, creating a much-needed last-mile support framework.”
On the occasion of the grant awards, the HCL Foundation released “Fifth Estate – NGOs Transforming Rural India in Environment, Health and Education,” a compendium featuring the top 30 NGOs selected in the sub-jury round, as well as the previous year’s winning NGOs.
For more information please visit www.hclfoundation.org/hcl-grant
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005593/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
